Dyadic International (NASDAQ:DYAI) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Dyadic International (NASDAQ:DYAI) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01), Zacks reports. The company had revenue of $0.45 million during the quarter, compared to analyst estimates of $1.43 million. Dyadic International had a negative net margin of 201.43% and a negative return on equity of 2,920.31%.

Here are the key takeaways from Dyadic International’s conference call:

• Q3 revenue fell 61% year over year to about $449,000, reflecting lower grant activity and the completion of prior-year R&D projects. Nine-month revenue was roughly flat at $2.5 million.
• Dyadic reported its first direct commercial sales of recombinant proteins, while partners expanded products based on its platforms; Inzymes’ first sale of a second chymosin product is expected to generate a $225,000 payment in Q4. Management cautioned that sales remain modest, customer adoption is slower than expected, and limited capital constrains inventory and growth.
• The expanded BRIG BIO–Strive Nutrition collaboration creates a potential path to supply bovine alpha-lactalbumin, with an initial 10-ton purchase and up to 200 tons in the following year contemplated. Those purchases depend on successful optimization, cost targets, product testing, and regulatory requirements.
• Dyadic highlighted C1 platform results including high-yield antibody production and a vaccine-antigen workflow completed in about 15 days; Gates-funded animal studies are underway, with results expected in Q1 2027. These are development milestones, and further validation and external funding will be needed to advance the programs.
• Dyadic ended Q3 with about $6 million in cash, restricted cash, and securities, after using approximately $5.3 million in operating cash during the first nine months; management expects cash use to remain at a similar level. The company raised $2.9 million gross in an offering and is evaluating financing and strategic options.

Dyadic International Stock Performance

NASDAQ DYAI traded down $0.02 during trading on Friday, hitting $0.33. The stock had a trading volume of 85,672 shares, compared to its average volume of 171,067. The company has a market capitalization of $13.30 million, a PE ratio of -1.44 and a beta of 1.10. The company’s 50-day moving average price is $0.42 and its two-hundred day moving average price is $0.74. Dyadic International has a 12 month low of $0.33 and a 12 month high of $1.60.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Dyadic International from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 16th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Dyadic International Company Profile

Dyadic International, Inc. is a biotechnology company focused on developing and commercializing microbial protein-expression technologies for the production of biologic products. Its platforms are designed to enable the efficient development and manufacture of proteins used in vaccines, therapeutics, food and nutrition products, and industrial applications. The company’s principal technology, the C1 expression platform, is based on a proprietary strain of the fungus Trichoderma reesei . Dyadic has also developed additional microbial systems, including the Dapibus platform, which is intended to support the production of proteins and other biological materials in yeast.